ASX:PVA / PSIVIDA CORP.

2018-04-19 globenewswire
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter of fiscal year 2018 on Tuesday, May 8, 2018. Management will host a conference call to review the results at 4:30 p.m. ET on the same day.
Upvote Downvote

2018-04-18 globenewswire
WATERTOWN, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting being held in Honolulu, Hawaii, from April 29 – May 3, 2018.
Upvote Downvote

2018-03-28 reuters
* PSIVIDA CORP. ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC. AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS – COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS, INC.
Upvote Downvote

2018-03-28 reuters
* PSIVIDA CORP ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS – COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS INC
Upvote Downvote

2018-03-28 globenewswire
Acquisition and additional funding significantly accelerate the company’s transformation to a specialty biopharmaceutical company with the potential to commercialize two ophthalmic products in 1H 2019
Upvote Downvote

2017-12-14 reuters
* PSIVIDA CORP - BASED ON STUDY FINDINGS, IMPLANT WAS WELL TOLERATED AND SHOWED POTENTIAL ANALGESIC EFFECTS THROUGH SIX-MONTH STUDY PERIOD Source text for Eikon: Further company coverage:
Upvote Downvote

2017-07-10 sec.gov
EX-99.1 Exhibit 99.1 pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida’s Revenue Generation WATERTOWN, MA., July 10, 2017 — pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release drug products and technologies, today announced an amendment of its exclusive license and collaboration agreement wi
Upvote Downvote

2017-07-10 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 10, 2017     pSivida Corp. (Exact Name of Registrant as Specified in Charter)       Delaware   000-51122   26-2774444 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.
Upvote Downvote

2017-07-10 reuters
* Psivida out-licenses emea rights for durasert™ three-year treatment for posterior segment uveitis while retaining u.s. Commercial rights; amended global collaboration agreement with alimera for iluvien® improves psivida’s revenue generation
Upvote Downvote

2017-06-30 sec.gov
EX-99.1 Exhibit 99.1 pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson WATERTOWN, Mass., June 28, 2017 — pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release drug products and technologies, today announced that Kristine Peterson, a seasoned healthcare executive has been elected to the Company’s Board of Directors.
Upvote Downvote

2017-06-30 sec.gov
EX-10.1 Exhibit 10.1 pSivida Short Term Incentive Plan Purpose pSivida’s Short Term Incentive (STI) Plan (the “Plan”) is designed to drive the achievement of Corporate Performance by providing employees the opportunity to receive discretionary Short Term Incentive Awards at the Compensation Committee’s discretion, including a variety of compensation vehicles such as Cash Bonuses based on Corporate Performance and Individual Performance each budget/performance year.
Upvote Downvote

2017-06-30 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 27, 2017     pSivida Corp. (Exact Name of Registrant as Specified in Charter)       Delaware   000-51122   26-2774444 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.
Upvote Downvote

2017-06-30 sec.gov
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints John Mercer, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or a director of pSivida Corp.
Upvote Downvote

2017-06-30 sec.gov
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints John Mercer, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or a director of pSivida Corp.
Upvote Downvote

2017-06-29 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2017     pSivida Corp. (Exact name of registrant as specified in its charter)       Delaware   000-51122   26-2774444 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote